Here's Why Spark Therapeutics Inc. Surged 23.5% in August
Shares of Spark Therapeutics Inc. (NASDAQ: ONCE), a clinical-stage biotech developing gene therapies, rose 23.5% in August, according to data from S&P Global Market Intelligence. The company pleased investors with clinical trial data for a hemophilia drug in early stage development.
The FDA recently accepted the company's first new drug application that could make Luxturna an important option for patients with a rare gene mutation that leads to blindness. It might be a phase 1/2 study, but early results for hemophilia A candidate SPK-8011 suggests that more candidates emerging from Spark Therapeutics' proprietary discovery platform could reach the agency's inbox in the years ahead.
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Stock
€28.35
1.870%
The stock is one of the favorites of our community with 28 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a positive potential of 44.65% compared to the current price of 28.35 € for Pfizer Inc..
